UNSPSC 51392218: Apraclonidine hydrochloride

This classification denotes an alpha-adrenergic agonist with the molecular formula C9H10Cl2N4.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier D2VW67N38H, chemically known as 2,6-dichloro-n-(4,5-dihydro-1h-imidazol-2-yl)benzene-1,4-diamine but more generally known as apraclonidine hydrochloride, which bears US NIH Compound Identifier 2216. European Medicines Agency schedules Apraclonidine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12926MIG.

Most nations, for tariff and trade purposes, schedule apraclonidine hydrochloride under HS 29332990. As of Q4 2014, APRACLONIDINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Apraclonidine hydrochloride bears US NLM identifiers UMLS ID C0304657 and NCI Concept Code C47401. SMILES: C1C(CC(C(C1CL)NC2=NCCN2)CL)N.CL.

UNSPSC 51392218 Apraclonidine hydrochloride is a Commodity code nominally describing a specific ophthalmic pharmaceutical agent, but recent state and local opportunities tagged under this code show a significant mismatch: the two most recent solicitations concern naloxone procurement and pharmacy benefit program management rather than apraclonidine hydrochloride itself. Seminole County, Florida issued an IFB in June 2026 for 1,900 units of naloxone and 800 safe drug deactivation systems annually, with quarterly deliveries to its Community Health Building in Sanford. The Texas Health and Human Services Commission posted an RFI in April 2026 to gather vendor capabilities on direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels. The code shows limited recent activity aligned with its actual pharmaceutical scope, suggesting either inconsistent tagging in state and local procurement systems or a shift in how jurisdictions classify pharmaceutical procurements.

The geographic spread of tagged activity is limited to Florida and Texas based on these two opportunities. Seminole County's naloxone IFB, due July 26, 2023, targets community health initiatives with fixed-fee pricing, quarterly deliveries, and a two-year initial term with optional one-year renewal; vendors must meet E-Verify, drug-free workplace, and insurance requirements, with potential FEMA funding triggering federal compliance obligations including the Clean Air Act and Federal Water Pollution Control Act. Texas HHS's RFI, due April 3, 2026, is exploratory market research into direct manufacturer contracting models that bypass traditional intermediaries—no award value, evaluation criteria, or formal timelines are established at this stage. The code sees sparse recent activity overall, and the opportunities present diverge substantially from the pharmaceutical scope implied by the UNSPSC name, signaling that this particular code may not be a reliable predictor of actual procurement demand for apraclonidine hydrochloride or related specialty pharmaceuticals.